Sanofi stops phase 3 study of riliprubart in rare nerve disease due to efficacy concerns
Science Seeking Alpha Jun 10, 2026
Sanofi stops phase 3 study of riliprubart in rare nerve disease due to efficacy concerns
Sanofi stops phase 3 study of riliprubart in rare nerve disease due to efficacy concerns
